Sanofi-aventis announces 2009 financial outcome

Sanofi-aventis has published its financial figures for the full year of 2009.

The group stated that it put in a “strong performance” enhanced by acquisitions, with sales growing in its emerging markets by 19 per cent and its diabetes division by 19.4 per cent.

Additionally, sales of vaccines rose by 19.2 per cent, while the group’s consumer healthcare operations underwent growth of 26.8 per cent.

Its total flu vaccine sales reached 1,062 million euros (931,967, 000 pounds) during the 12-month period, 440 million euros of this constituting its H1N1 therapy.

Chief executive officer of the firm Christopher Viehbacher commented that 2009 also saw the first phase of Sanofi-aventis’ new strategy.

“Major steps have already been achieved in strengthening our growth platforms and reinforcing our research and development pipeline while delivering a double-digit EPS growth,” he continued.

In January, Sanofi-aventis entered into an agreement with Chattem that will see the global pharmaceutical organisation purchase all outstanding shares in the firm.